Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 425

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Dimopoulos, Meletios A., Sonneveld, Pieter, Leung, Nelson, Merlini, Giampaolo, Ludwig, Heinz, Kastritis, Efstathios, Goldschmidt, Hartmut, Joshua, Douglas, Orlowski, Robert Z., Powles, Raymond, Vesole, David H., Garderet, Laurent, Einsele, Hermann, Palumbo, Antonio, Cavo, Michele, Richardson, Paul G., Moreau, Philippe, San Miguel, Jesús, Rajkumar, S. Vincent, Durie, Brian G.M., Terpos, Evangelos·2016·Journal of Clinical Oncology

Abstract

Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m 2 to 140 mg/m 2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.65.0044

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 425

Metadata

Authors
Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., Goldschmidt, H., Joshua, D., Orlowski, R. Z., Powles, R., Vesole, D. H., Garderet, L., Einsele, H., Palumbo, A., Cavo, M., Richardson, P. G., Moreau, P., San Miguel, J., Rajkumar, S. V., Durie, B. G. M., & Terpos, E.
Venue
Journal of Clinical Oncology
Published
2016-05-01
Volume
34
Issue
13
Pages
1544-1557
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2299833483
Cited by
425
References
82
FWCI
32.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. https://app.cochat.ai/papers/10.1200/jco.2015.65.0044
The paper
Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., Goldschmidt, H., Joshua, D., Orlowski, R. Z., Powles, R., Vesole, D. H., Garderet, L., Einsele, H., Palumbo, A., Cavo, M., Richardson, P. G., Moreau, P., San Miguel, J., Rajkumar, S. V., . . . Terpos, E. (2016). International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.0044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.